Overexpression of an activated REL mutant enhances the transformed state of the human B-lymph...

This work was made openly accessible by BU Faculty. Please share how this access benefits you. Your story matters.

| Version | Citation (published version): |
|---------|------------------------------|
|         | M Chin, M Herscovitch, N Zhang, DJ Waxman, TD Gilmore. 2009. "Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile." Oncogene, Volume 28, Issue 20, pp. 2100 - 2111. |

https://hdl.handle.net/2144/27124

Boston University
Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile

M Chin1, M Herscovitch1, N Zhang, DJ Waxman, and TD Gilmore*
Department of Biology, Boston University, Boston, MA 02215, USA

Abstract

The human REL proto-oncogene encodes a transcription factor in the NF-κB family. Overexpression of REL is acutely transforming in chicken lymphoid cells, but has not been shown to transform any mammalian lymphoid cell type. In this report, we show that overexpression of a highly transforming mutant of REL (RELΔTAD1) increases the oncogenic properties of the human B-cell lymphoma BJAB cell line, as demonstrated by increased colony formation in soft agar, tumor formation in SCID mice, and adhesion. BJAB-RELΔTAD1 cells also show decreased activation of caspase in response to doxorubicin. BJAB-RELΔTAD1 cells have increased levels of active nuclear REL protein as determined by immunofluorescence, subcellular fractionation, and electrophoretic mobility shift assay. Overexpression of RELΔTAD1 in BJAB cells has transformed the gene expression profile of BJAB cells from that of a germinal center B-cell subtype of diffuse large B-cell lymphoma (GCB-DLBCL) to that of an activated B-cell subtype (ABC-DLBCL), as evidenced by increased expression of many ABC-defining mRNAs. Upregulated genes in BJAB-RELΔTAD1 cells include several NF-κB targets that encode proteins previously implicated in B-cell development or oncogenesis, including BCL2, IRF4, CD40 and VCAM1. The cell system we describe here may be valuable for further characterizing the molecular details of REL-induced lymphoma in humans.

Keywords
c-Rel; NF-kappaB; malignant transformation; BJAB; lymphoma; microarray

Introduction

The human c-rel proto-oncogene (REL) encodes an NF-κB family transcription factor. Misregulated REL is associated with B-cell malignancies in several ways (Gilmore et al., 2004). Overexpression of REL protein can transform chicken lymphoid cells in vitro. Additionally, the REL locus is amplified in several types of human B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma and primary...
mediastinal lymphoma. Moreover, REL mRNA is highly expressed in de novo DLBCLs, and this elevated expression correlates with increased expression of many putative REL target genes (Rhodes et al., 2005). Nevertheless, REL has not been shown to be oncogenic in any mammalian B-cell system, either in vitro or in vivo.

REL contains an N-terminal Rel Homology Domain, which mediates DNA binding, dimerization, nuclear localization, and binding to its inhibitor IκB. The C-terminal half of REL contains a transactivation domain, which can be divided into two subdomains (Martin et al., 2001; Starczynowski et al., 2003). Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of REL in chicken spleen cells (Starczynowski et al., 2003). Similarly, v-Rel lacks a transactivation subdomain found in avian c-Rel, and this deletion contributes to v-Rel’s increased transforming activity as compared to c-Rel (Gilmore, 1999). In addition, deletions and mutations that alter the REL transactivation domain have been identified in a small percentage of human B-cell lymphomas, and one such mutation can enhance the transforming activity of REL in chicken lymphoid cells (Kalaitzidis and Gilmore, 2002; Barth et al., 2003; Starczynowski et al., 2007). Nevertheless, REL’s role in mediating oncogenesis in mammalian cells is not clear.

Herein, we show that overexpression of a REL mutant lacking transactivation subdomain 1 (RELΔTAD1) enhances certain “transformed” properties of the human B-lymphoma cell line BJAB. Furthermore, RELΔTAD1-transformed BJAB cells have an altered gene expression profile that is consistent with them having been converted to a more aggressive form of DLBCL. As such, these results are the first direct demonstration that REL can contribute to human B-cell oncogenesis and describe an in vitro system for studying oncogenic conversion of B-cell lymphoma.

Results

Overexpression of RELΔTAD1 increases oncogenic properties of BJAB cells

A REL mutant (RELΔ424-490, or RELΔTAD1 herein) that is missing the first C-terminal transactivation subdomain has an enhanced ability to transform primary chicken spleen cells in vitro as compared to wild-type REL (Starczynowski et al., 2003). In an effort to establish a human cell assay for REL-induced oncogenesis, we first created an MSCV-based retroviral vector for expression of RELΔTAD1; as a control for our experiments, we used the MSCV vector backbone that contains only the puromycin resistance gene (Figure 1a).

Retroviral stocks of MSCV and MSCV-RELΔTAD1 were used to infect human B-lymphoma BJAB cells, and these cells were then selected for puromycin resistance to establish stable pools of retrovirally transduced cells. By Western blotting, we identified a pool of MSCV-RELΔTAD1-transduced cells that expresses high levels of RELΔTAD1, which migrates faster than full-length endogenous REL (Figure 1b). The expression of RELΔTAD1 is approximately 2.4-fold greater than endogenous REL, which is expressed at approximately equal levels in both MSCV-RELΔTAD1-transduced cells and control MSCV-transduced cells. The expression of RELΔTAD1 was stable during more than six months of continued passage of MSCV-RELΔTAD1-transduced cells (not shown).
To determine whether overexpression of RELΔTAD1 affects oncogenic properties of the BJAB cell line, we first compared the soft agar colony-forming abilities of MSCV-RELΔTAD1 cells and MSCV-transduced cells. As shown in Figure 1c, BJAB-RELΔTAD1 cells had an approximately 2.3-fold increased ability to form colonies in soft agar as compared to BJAB-MSCV cells. Moreover, colonies formed by BJAB-RELΔTAD1 cells were generally larger than those formed by BJAB-MSCV cells (not shown). Similarly, BJAB-RELΔTAD1 cells had increased tumor-forming ability in SCID mice (Table 1). Nevertheless, the growth rates of BJAB-MSCV and BJAB-RELΔTAD1 cells in liquid media were similar (Figure 1d). Doxorubicin-induced activation of caspase-3 and cleavage of the caspase substrate PARP are delayed in BJAB-RELΔTAD1 cells as compared to BJAB-MSCV cells; however, there is no difference in the ability of doxorubicin to decrease viability in these two cell types (Figure 1e).

**RELΔTAD1-expressing BJAB cells have increased nuclear REL protein activity**

As a first step towards determining the basis for the enhanced transformed properties of BJAB-RELΔTAD1 cells, we characterized RELΔTAD1 protein in these cells. By biochemical subcellular fractionation, BJAB-RELΔTAD1 cells showed increased nuclear REL protein—for both RELΔTAD1 and endogenous REL—as compared to BJAB-MSCV cells, in which the low level of endogenous REL is almost exclusively cytoplasmic (Figure 2a). As controls for these fractionation experiments, we show that two cytoplasmic proteins (CD40 and 14-3-3) and a nuclear protein (RNA polymerase) are exclusively present in their respective fractions in both cell types. Indirect immunofluorescence showed that BJAB-RELΔTAD1 cells have increased overall REL staining as compared to BJAB-MSCV cells and also have detectable nuclear REL staining (Figure 2b), which is not seen in BJAB-MSCV cells. Nuclear extracts from BJAB-RELΔTAD1 cells also have increased levels of NF-κB p50, but not of RelA (Figure 2c).

BJAB-RELΔTAD1 cells show increased nuclear κB-site DNA-binding activity as compared to BJAB-MSCV cells (Figure 2d). The κB site-binding activity in BJAB-RELΔTAD1 cells was competed by the relevant unlabelled probe and was almost completely supershifted by anti-REL antiserum. Therefore, by three criteria, nuclear REL protein is increased in BJAB-RELΔTAD1 cells as compared to control BJAB-MSCV cells.

In coimmunoprecipitations from BJAB cells, REL and RELΔTAD1 interact equally well with IκBα, suggesting that the changes in DNA binding and nuclear localization seen in BJAB-RELΔTAD1 cells are not due to changes in association with IκB (Supplementary Figure S1).

**The expression of many known REL/NF-κB target genes is increased in RELΔTAD1-expressing BJAB cells**

We next compared the overall gene expression profiles of BJAB-RELΔTAD1 cells and BJAB-MSCV cells by using an extensive human microarray, which contains over 41,000 probes, representing unique gene products. Using a two-fold change and P-value of less than 0.005 (Holloway et al., 2008), we found that 538 mRNAs were decreased and 663 mRNAs were increased in BJAB-RELΔTAD1 cells (Supplementary Table S1).
transcripts were increased at least ten-fold in BJAB-RELΔTAD1 cells (Table 2). Serving as an internal control, REL mRNA showed approximately 25-fold increased expression in BJAB-RELΔTAD1 cells, presumably because the REL probe on the microarray can detect both endogenous REL and exogenous RELΔTAD1 mRNA/cDNA.

Several mRNAs that show greatly elevated expression in BJAB-RELΔTAD1 cells are known REL/NF-κB targets, including CXCR7 (77-fold increase), IRF4 (32-fold), CD44 (26-fold), VCAM1 (24-fold), chemokine CCL22 (21-fold) and the anti-apoptotic protein BCL2 (13.5-fold). However, out of approximately 400 reported REL/NF-κB targets (see www.nfkb.org), only approximately 4% were at least two-fold elevated in BJAB-RELΔTAD1 cells, 94% were unchanged, and 2% were decreased by at least two-fold.

Based on cDNA profiling, DLBCLs have been divided into two main subtypes: GCB (germinal center B-cell type) and ABC (activated B-cell type) (Alizadeh et al., 2000; Rosenwald et al., 2002; Shipp et al., 2002; Wright et al., 2002; Ngo et al., 2006). This division is based on the observation that one subset of DLBCLs has a gene expression profile similar to B lymphocytes in the germinal center while another subset has a gene expression profile similar to activated peripheral B cells (Alizadeh et al., 2000). Furthermore, the ABC subtype has increased expression of several NF-κB target genes as compared to the GCB subtype, and survival of ABC cell lines depends on expression of these NF-κB target genes (Davis et al., 2001, Lam et al., 2008). BJAB cells have a gene expression profile that is consistent with the GCB subtype (Kalaitzidis et al., 2002; Ngo et al., 2006). Using the literature, we assembled a comprehensive set of genes that have been used to define these two subsets of DLBCL: 102 for ABC and 62 for GCB (see Tables S2 and S3 for details). We then compared the levels of these ABC- and GCB-defining targets between BJAB-MSCV cells and BJAB-RELΔTAD1 cells, using a P-value < 0.005 as a cut-off. Overall, 30% of the 102 ABC-profile genes were upregulated in the BJAB-RELΔTAD1 cells (Table 3). We also found that BJAB cells overexpressing RELΔTAD1 showed increased expression of many of the ABC-defining genes that are NF-κB targets (Figure 3a): 17/29 (59%) ABC-specific NF-κB target genes were upregulated in BJAB-RELΔTAD1 cells (Table 3). Using the same filter criteria (P<0.005), only 6% of total transcripts showed increased expression in BJAB-RELΔTAD1 cells as compared to BJAB-MSCV cells.

We also found that 24% of the GCB-defining genes were downregulated in BJAB-RELΔTAD1 cells as compared to BJAB-MSCV cells (Table 3). In contrast, only 9% of the total transcripts were downregulated in BJAB-RELΔTAD1 cells.

A statistical comparison of the percent change in ABC-subtype genes (30% upregulated, 12% downregulated) versus GCB-subtype genes (10% upregulated, 24% downregulated) in BJAB-RELΔTAD1 cells (as compared to BJAB-MSCV cells) indicates that these two gene sets are affected in a significantly different manner (P-value, 0.0009; see Table 3).

To further analyze our gene expression data, we used Gene Ontology (http://david.abcc.ncifcrf.gov/) to categorize genes upregulated in BJAB-RELΔTAD1 cells. We focused on upregulated genes because REL is primarily a transcriptional activator. Using this analysis, we were able to classify 563 of the 663 upregulated genes (>2-fold, P<0.005)
in BJAB-RELΔTAD1 cells; many of these upregulated genes encode proteins associated with cell surface processes/regions, including ones involved in cell-cell communication, the plasma membrane, the extracellular matrix, biological adhesion and signal transduction in general (Table 4).

In addition, we classified this same set of upregulated genes in BJAB-RELΔTAD1 cells by their biological function (www.ingenuity.com); by this analysis we were able to classify 421 of 663 significantly upregulated genes. This analysis was consistent with our Gene Ontology annotation. Namely, over-represented molecular and cellular functions included those involved in cell-to-cell communication and cell growth and proliferation (Table 4). Furthermore, many genes (75 out of 421 annotated) that are statistically over-represented have been associated with immunological diseases (Table 4).

We next used RT-PCR to validate a subset of genes showing increased expression in BJAB-RELΔTAD1 cells. As controls, we used a primer set that could amplify both endogenous REL and RELΔTAD1 to show that REL mRNA expression is increased in BJAB-RELΔTAD1 cells as compared to BJAB-MSCV cells, whereas GAPDH expression is similar in both cell types (Figure 3b). Consistent with the microarray results, there was increased expression of BCL2, CCR7, IRF4 and VCAM1 mRNA in BJAB-RELΔTAD1 cells. In contrast, CD10, a marker for GCB-type DLCBL (van Imhoff et al., 2006), showed reduced mRNA expression in BJAB-RELΔTAD1 cells. Western blotting showed that protein levels of BCL2, VCAM1, CD40 and REL are all elevated in BJAB-RELΔTAD1 cells (Figure 3c), whereas CD10 protein is reduced in BJAB-RELΔTAD1 cells (Figure 3c). For CD40, the small (1.4-fold), but significant (P ≤8.97 × 10^-11), increase in CD40 mRNA in BJAB-RELΔTAD1 cells seen on the microarray was mirrored by an approximately 1.4-fold increase in CD40 protein.

**BJAB-RELΔTAD1 cells show increased adherence to culture dishes**

During passage, we noticed that BJAB-RELΔTAD1 cells appeared to adhere more readily to culture plates than BJAB-MSCV cells. To compare the abilities of BJAB-MSCV and BJAB-RELΔTAD1 cells to adhere, we plated both cell types on petri dishes, and cultured the cells for 36 h. We then visualized these cells before and after washing with PBS. As shown in Figure 4a, many BJAB-RELΔTAD1 cells remained attached to the culture dish after washing, whereas the BJAB-MSCV cells were removed by washing. We quantified this difference in adherence by comparing the numbers of floating versus adhering cells for each cell type: approximately five-fold more BJAB-RELΔTAD1 cells were attached to the dish as compared to the BJAB-MSCV cells (Figure 4b).

**BJAB cells have low levels of endogenous REL protein expression**

BJAB cells have previously been shown to have a low level of REL mRNA as compared to a number of other lymphoma cell lines (Leeman et al., 2008). To determine whether REL protein expression was also low in BJAB cells, we compared the expression of endogenous REL protein in BJAB cells to five other human B-cell lymphoma cell lines (SUDHL-4, RC-K8, IB4, BL41 and Daudi). SUDHL-4 cells have been characterized as having a GCB profile, whereas RC-K8 cells have an ABC cDNA expression profile (Kalaitzidis et al.,...
Among these six lymphoma cell lines, the expression of REL was lowest in BJAB cells (Figure 5a). As such, in BJAB cells, retrovirally transduced expression of RELΔTAD1 is higher than endogenous REL, whereas in Daudi cells, RELΔTAD1 expression is lower than endogenous REL (Figure 5b). Moreover, expression of RELΔTAD1 did not enhance the soft agar colony ability of Daudi cells (Figure 5c), at least when expressed at the level in the cell line we analyzed here.

Discussion

This paper represents the first direct demonstration of an oncogenic effect of REL protein expression in a human B-lymphoid cell system. That is, we show that overexpression of an activated REL mutant, RELΔTAD1, increases the oncogenic properties of the human B-cell lymphoma BJAB cell line, as measured by increased soft agar colony-forming ability, tumor formation in immunocompromised mice, and adhesion. Moreover, the mRNA expression profile of BJAB cells overexpressing RELΔTAD1 is substantially altered; in particular, there is increased expression of many NF-κB target genes whose expression is associated with the more aggressive ABC subtype of diffuse large B-cell lymphoma. Furthermore, many of the up-regulated genes in BJAB-RELΔTAD1 cells can be classified as genes implicated in immunological diseases (Table 4), suggesting that BJAB-RELΔTAD1 cells have a phenotype that is more similar to aggressive DLBCL than is the GCB-like phenotype of control BJAB cells. As such, the cell system we describe here may provide an in vitro model system for understanding DLBCL transition from a low-grade (GCB-like) to a high-grade (ABC-like) oncogenic state.

Although v-Rel, c-Rel and their derivatives have been shown to be oncogenic in avian and mouse systems (Gilmore, 1999; Gilmore et al., 2004), there has been controversy about whether REL is a true oncoprotein for human B-lymphoid cells (Shaffer et al., 2002; Houldsworth et al., 2004). For example, the REL gene is amplified in a high percentage of GCB-type DLBCLs, but these cells do not have particularly high levels of nuclear κB site-binding activity (Davis et al., 2001). Moreover, the lack of oncogenic activity by overexpressed REL in mouse B-lymphoid cells in vitro or in vivo has cast doubt on whether REL acts as an oncoprotein in human B-cell malignancies, which are the sole human cancer cell type wherein the REL gene has been found to undergo amplification and mutation (Gilmore et al., 2004). The results we present herein strongly suggest that REL can exert an oncogenic effect in human B-lymphoma cells, and indicate that REL or certain REL target genes may be suitable therapeutic targets for some human B-cell lymphomas.

There are several likely explanations for the susceptibility of BJAB cells to the transforming activity of RELΔTAD1. First, BJAB cells express relatively low levels of endogenous REL protein (Figure 5a) as compared to several other human B-lymphoma cell lines. Thus, in BJAB cells it is possible to achieve a higher ratio of RELΔTAD1 protein to endogenous REL, and this relatively high level of RELΔTAD1 may be required for its transforming effect in human B cells. Second, BJAB cells have a GCB mRNA profile (Ngo et al., 2006), which is correlated with a better clinical outcome in DLBCL patients (Rosenwald et al., 2002; Shipp et al., 2002), suggesting that BJAB cells are not as “transformed” as some other human B-cell lines. Third, in soft agar and tumor-forming assays similar to those we have...
conducted here, BJAB cells have been shown to be susceptible to oncogenic effects of other factors, including the Epstein-Barr virus (EBV) LMP1 protein (Enberg et al., 1983; Wennborg et al., 1987), EBV small RNAs (Yamamoto et al., 2000) and the AP12-MALT1 fusion protein from MALT lymphomas (Ho et al., 2005). Interestingly, LMP1 and AP12-MALT1 are both inducers of NF-κB (Hammarskjold et al., 1992; Lucas et al., 2007) and both can increase the resistance of BJAB cells to inducers of apoptosis (Stoffel et al., 2004; Ho et al., 2005; Lucas et al., 2007). In addition, LMP1 can induce expression of BCL2 and IRF4, which are required for apoptosis resistance (Henderson et al., 1991; Finke et al., 1992; Snow et al., 2006), enhanced adhesion (Mainou and Raab-Traub, 2006), and cell motility (Mainou and Raab-Traub, 2006). Moreover, MALT1 chromosomal gains are also associated with ABC-subtype gene expression, including high levels of BCL2 expression and poorer prognosis (Dierlamm et al., 2008).

Many of the upregulated genes in BJAB-RELΔTAD1 cells are connected with processes that involve the plasma membrane, i.e., cell-to-cell communication, the extracellular matrix, adhesion, and membrane binding (see Table 4). These genes include VCAM1, CD44, CD40, ITGAX, and many chemokines and chemokine receptors including CCL22, CCR7, CXCR4 and CXCL10. Additionally, BJAB-RELΔTAD1 cells are more adherent to a culture dish than control BJAB-MSCV cells (Figure 4). This is consistent with the large cohort of increased cDNAs in RELΔTAD1 cells that are classified as related to adhesion (Table 4). NF-κB signaling is also known to be downstream of many adhesion-related signaling pathways (Perez et al., 1994; Lee et al., 1999; Zarnegar et al., 2004). Furthermore, CD40 and VCAM1 mRNA and protein expression are upregulated in the BJAB-RELΔTAD1 cells. While CD40 mRNA was only modestly increased (1.4-fold) in BJAB-RELΔTAD1 cells, this did translate into similarly increased CD40 protein levels (Figure 3c). CD40 has been shown to be important in B-cell aggregation (Lee et al., 1999), and both VCAM1 and CD40 play roles in adhesion (Springer and Vonderheide, 1992; Lee et al., 1999). Taken together, these results suggest that overexpression of RELΔTAD1 in BJAB cells causes upregulation of many adhesion-associated genes, which results in a phenotype of the cells being more adherent, which may contribute to their enhanced ability to form colonies in soft agar and tumors in SCID mice.

BCL2 and IRF4, genes whose expression is up-regulated in BJAB-RELΔTAD1 cells, are markers for ABC DLBCL, whereas CD10 is down-regulated in both ABC DLBCLs and BJAB-RELΔTAD1 cells (Alizadeh et al., 2000; Wright et al., 2003). The increased expression of BCL2 in ABC DLBCLs correlates with a poorer clinical prognosis (Iqbal et al., 2006). The transcription factor IRF4 can synergize with v-Rel in the transformation of chicken fibroblasts and knockdown of IRF4 expression reduces the soft agar colony-forming ability of v-Rel-transformed cells (Hrdlicková et al., 2001). Of note, multiple myelomas are dependent on IRF4 for growth, whereas the growth of GCB-DLCBL does not require IRF4 (Shaffer et al., 2008). Taken together, these results are consistent with BCL2 and IRF4 playing a role in the enhanced transformed phenotype that we describe for BJAB-RELΔTAD1 cells.

We also found that many other ABC-defining genes (including several not known to be NF-κB targets) are significantly upregulated in BJAB-RELΔTAD1 cells. These ABC genes
include *MARCKS, BATF, BMI1, LITAF* and others (see Tables 2 and S2). Some of these ABC-type upregulated genes may reflect an overall shift in gene expression, induced indirectly by NF-κB/REL. In addition, some GCB-subtype genes are significantly down-regulated in BJAB-RELΔTAD1 cells (Tables 3 and S3). These genes are, for the most part, non-NF-κB targets, suggesting that these decreases in GCB-type gene expression are also indirectly affected by RELΔTAD1.

Approximately 4% of total NF-κB targets ([www.nf-kb.org](http://www.nf-kb.org)) were up-regulated in BJAB-RELΔTAD1 cells as compared to 59% of ABC-specific NF-κB targets (Table 2). The selective increase in expression of only a small number of NF-κB target genes in BJAB-RELΔTAD1 cells suggests that the BJAB cells have been transformed to a more aggressive form of DLBCL by RELΔTAD1 through activation of a minor subset of NF-κB/REL targets. These ABC-specific NF-κB target genes may be poised for activation by RELΔTAD1 in B-lymphoma cells, possibly due to their chromosomal state or to cooperation of RELΔTAD1 with other B cell-specific transcription factors.

There are 40 genes whose expression is reduced by at least ten-fold in BJAB-RELΔTAD1 cells (Table S1). The reduced expression of CD10 mRNA and protein in BJAB-RELΔTAD1 cells (Figure 3) is consistent with the enhanced transformed properties of these cells, given that reduced CD10 expression correlates with a poorer prognosis in the clinic (van Imhoff *et al.*, 2006). Gupta *et al.* (2008) have shown that expression of two B-cell proteins BLNK and BCAP are down-regulated directly by Rel in v-Rel-transformed avian cells. In our study, the level of only BLNK was significantly reduced in BJAB-RELΔTAD1 cells. Such results raise the possibility that down-regulation of gene expression is important for REL-induced effects on B-cell oncogenesis, and that some of these genes are specifically repressed by RELΔTAD1.

BJAB-RELΔTAD1 cells show a reduced induction of caspase-3 activity following treatment with 1 μg/ml doxorubicin, although the ability of doxorubicin to decrease viability is unchanged in BJAB-RELΔTAD1 cells (Figure 1e). These data are consistent with previous results showing that CD40 ligand, an inducer of NF-κB, can reduce the ability of this concentration of doxorubicin to induce caspase activity in BJAB cells without affecting its ability to induce apoptosis (Voorzanger-Rousselot *et al.*, 1998). These results indicate that doxorubicin induces apoptosis in BJAB cells through a caspase-independent mechanism, which is not blocked by increased Rel/NF-κB activity.

The majority of the nuclear κB site-binding activity in RELΔTAD1-BJAB cells contains REL protein, whereas in control BJAB-MSCV cells, only a small fraction of the binding activity is supershifted by REL antiserum (Figure 2d). In addition, there are increased nuclear levels of NF-κB p50 in BJAB-RELΔTAD1 cells, presumably because RELΔTAD1 and p50 readily interact (Figure S1). Taken together, these data suggest that a shift in the composition of nuclear NF-κB/REL dimers occurs upon overexpression of RELΔTAD1.

Only a small number of the genes upregulated by more than ten-fold in BJAB-RELΔTAD1 cells are ABC-defining (5 genes) or known NF-κB targets (8 genes) (Table 2). As such, some of these genes may be novel ABC DLBCL markers or NF-κB/REL targets. In
addition, there are 14 ABC-defining genes that are significantly up-regulated in BJAB-RELΔTAD1 cells that have yet to be classified as NF-κB/REL targets (Tables 3 and S2). Future work will be directed at determining which genes are direct RELΔTAD1 targets and which contribute to the phenotypic changes that occur in RELΔTAD1 “transformed” BJAB cells.

Material and methods

Plasmids, cell culture and infections

pMSCV has been described previously (Gilmore et al., 2003). pMSCV-RELΔTAD1 was created by subcloning a BglII to XhoI fragment containing the RELΔTAD1 cDNA into pMSCV.

Human A293T cells and BJAB or Daudi lymphoma cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 or 20% fetal bovine serum (Biologos, Montgomery, IL), respectively, as described (Starczynowski et al., 2005). Virus stocks were generated by transfecting A293T cells with pMSCV or pMSCV-RELΔTAD1 plus helper plasmid pcl10a1, essentially as described previously (Gilmore et al., 2003). Approximately two days later, virus was harvested. One ml of virus (in the presence of 4 μg/ml polybrene) was used to infect 10⁶ BJAB or Daudi cells using the spin infection method (Gilmore et al., 2003). Two days later, cells were selected with 2.5 μg/ml puromycin (Sigma) for 2-4 weeks.

Soft agar colony assays and tumor formation assays

For soft agar assays, equal numbers of the indicated BJAB or Daudi cells (250, 500, 1000 or 2000 cells) were placed in soft agar containing DMEM, 20% FBS and 0.3% bacto agar (Difco, Franklin Lakes, NJ), and plates were placed at 37°C in a humid incubator with 5% CO₂. To confirm cell counts, total cell protein assays (Bio-Rad) were performed on the cell dilutions used for plating. Macroscopic soft agar colonies were counted 14 days after plating.

Tumor studies were performed essentially as described previously (Yamamoto et al., 2000; Gapuzan et al., 2002). 5 x 10⁶ cells were injected subcutaneously into SCID mice (Taconic Farms, Germantown, NY). Once tumors appeared, mice were monitored 3x weekly and animals were sacrificed when tumors reached 2.25 mm². All animal studies were performed in accordance with NIH guidelines and with approval of the Boston University Institutional Animal Care and Use Committee.

Caspase-3 and cell viability assays

Caspase-3 activity and cell viability following doxorubicin treatment were performed as described in Supplementary Material.
Western blotting, indirect immunofluorescence, biochemical fractionation and electrophoretic mobility shift assays

Western blotting and indirect immunofluorescence were performed as described previously (Starzynowski et al., 2003, 2005). Details of antisera are in Supplementary Material. Indirect immunofluorescence was visualized using a confocal microscope (Olympus FLUOVIEW Laser Scanner Microscope BX 50, Center Valley, PA) (Starzynowski et al., 2003).

Cytoplasmic and nuclear extracts were prepared as described previously (Liang et al., 2003), and were used either for Western blotting of equalized fractions or in electrophoretic mobility shift assays (nuclear extracts). EMSAs for κB-site binding were performed using 5 μg of nuclear extracts as described previously (Kalaitzidis et al., 2002). For supershift assays, 1 μl of REL antiserum (#1507, gift of Nancy Rice) was added after protein/DNA complex formation, and samples were then incubated for an additional hour on ice (Kalaitzidis et al., 2002).

mRNA analysis: microarrays, data analysis and reverse transcriptase-PCR

The Agilent Whole Human Genome Microarray platform (product number G4112, Agilent Technology, Santa Clara, CA). This array contains 43,376 human oligonucleotide probes and also 1,468 positive controls and 153 negative controls. Within the array there are approximately 41,000 unique probes, which represent a smaller number of genes, reflecting the redundancy of the array platform. RNA was isolated from ~ 5 × 10⁶ BJAB-MSCV and BJAB-RELΔTAD1 cells from four separate dishes for each on four separate days using Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA). RNA integrity was measured using an Agilent 2100 Bioanalyzer (Agilent Technology, Santa Clara, CA), and all samples had integrity values over 8.0. Samples from two RNA aliquots for each cell type were pooled, creating four pooled RNA samples: two of BJAB-MSCV and two of BJAB-RELΔTAD1 cells. Sample labeling, hybridization to microarrays, scanning and calculation of normalized expression ratios were performed as previously described (Holloway et al., 2008) at the Wayne State University Institute of Environmental Health Sciences microarray facility. As part of the platform, a dye swapping experiment was performed, where Alexa 555-labeled cDNA from one of the BJAB-MSCV pools was mixed with Alexa 647-labeled cDNA from one of the BJAB-RELΔTAD1 pools. In a reciprocal dye swap, Alexa 647-labeled cDNA from BJAB-MSCV cells was mixed with Alexa 555-labeled cDNA from BJAB-RELΔTAD1 cells.

The false discovery rate (FDR) was calculated as described previously (Clodfelter et al., 2007). Briefly, a filter of P<0.005 was applied for statistical significance. Of the total probes on the array, 1592 met the two-fold expression difference cut-off criterion between the two cell types. The number of genes predicted to meet the combined threshold (P<0.005 and a greater than two-fold change in expression) by type I errors is 0.005 × 1592, or 8 genes. In our array, the actual number of genes having a two-fold expression change and a P<0.005 is 1274. This corresponds to an FDR of 0.63% (8/1274). To eliminate duplicates in this analysis, we removed those genes with identical sequence names.
RT-PCR was performed as described (Leeman et al., 2008). See Supplementary Material for details of primers and PCR conditions.

**Adhesion assay**

BJAB-MSCV and BJAB-RELΔTAD1 cells (1 × 10^6) were plated on petri dishes and were cultured for 36 h at 37°C and imaged. Cells were then washed once with PBS and the same field was imaged again using the same magnification (200 ×). To quantify the number of attached and floating cells, cells from triplicate dishes of each cell type were also isolated directly from the media and cells that remained adhered were collected separately. Both pools of cells were then lysed, and total protein was quantified from these lysates.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgements**

We thank M Belmonte for help with tumor injections and microarray analysis, and M Garbati, J Leeman, D Kalaitzidis and D Starczynowski for helpful discussions. MC was supported by a Beckman Foundation Undergraduate Scholarship, MH was partially supported by a Pre-doctoral Fellowship from the Natural Sciences & Engineering Research Council of Canada, and NZ was partially supported by the Boston University Undergraduate Research Opportunities Program. This work was supported in part by the Superfund Basic Research Program at Boston University 5 P42 ES07381 (DJW) and NIH Grant CA047763 (TDG).

**References**

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403:503–511. [PubMed: 10676951]

Barth TF, Martin-Subero JI, Joos S, Menz CK, Hasel C, Mechtersheimer G, et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood. 2003; 101:3681–3686. [PubMed: 12511414]

Clodfelter KH, Miles GD, Wauthier V, Holloway MG, Zhang X, Hodor P, et al. Role of STAT5a in regulation of sex-specific gene expression in female but not male mouse liver revealed by microarray analysis. Physiol Genomics. 2007; 31:63–74. [PubMed: 17536022]

Dierlamm J, Murga Penas EM, Bentink S, Wessendorf S, Berger H, Hummel M, et al. Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma. Haematologica. 2008; 93:688–696. [PubMed: 18367485]

Enberg I, Klein G, Biovanella BC, Stehlin J, McCormick KJ, Andersson-Anvret M, et al. Relationship between the amounts of EBV-DNA and EBNA per cell, clonability and tumorigenicity in two EBV-negative lymphoma lines and their EBV-converted cell lines. Int J Cancer. 1983; 31:163–169. [PubMed: 6298125]

Feuerhake F, Kukol JL, Monti S, Chen W, LaCasce AS, Cattoretti G, et al. NF-κB activity, function and target gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005; 106:1392–1399. [PubMed: 15870177]

Finke J, Fritzten R, Ternes P, Trivedi P, Bross KJ, Lange W, et al. Expression of bcl-2 in Burkitt’s lymphoma cell lines: induction by latent Epstein-Barr virus genes. Blood. 1992; 80:459–469. [PubMed: 13783211]

Gapuzan M-E, Yufit PV, Gilmore TD. Immortalized embryonic mouse fibroblasts lacking the RelA subunit of transcription factor NF-κB have a malignantly transformed phenotype. Oncogene. 2002; 21:2484–2492. [PubMed: 11971183]
Gilmore TD. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene. 1999; 18:6925–6937. [PubMed: 10602467]

Gilmore TD, Jean-Jacques J, Richards R, Cormier C, Kim J, Kalaitzidis D. Stable expression of the avian retroviral oncoprotein v-Rel in avian, mouse, and dog cell lines. Virology. 2003; 316:9–16. [PubMed: 14599786]

Gilmore TD, Kalaitzidis D, Liang M-C, Starczynowski DT. The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene. 2004; 23:2275–2286. [PubMed: 14755244]

Gupta N, Delrow N, Drawid A, Sengupta AM, Fan G, Gélinas C. Repression of B-cell linker (BLNK) and B-cell adaptor for phosphoinoside 3-kinase (BCAP) is important for lymphocyte transformation by Rel proteins. Cancer Res. 2008; 68:808–814. [PubMed: 18245482]

Hammarskjold ML, Simurda MC. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-κB activity. J Virol. 1992; 66:6496–6501. [PubMed: 1404600]

Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 1991; 65:1107–1115. [PubMed: 1648447]

Ho L, Davis RE, Conne B, Chappuis R, Berczy M, Mhawech P, et al. MALT1 and the AP12-MALT1 fusion act between CD40 and IKK and confer NF-κB-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood. 2005; 105:2891–2899. [PubMed: 15598810]

Holloway MG, Miles GD, Dombkowski AA, Waxman DJ. Liver-specific hepatocyte nuclear factor-4α deficiency: greater impact on gene expression in male than in female mouse liver. Mol Endocrinol. 2008; 22:1274–1286. [PubMed: 18276827]

Houldsworth J, Oshen AB, Cattoretti G, Donnelly GB, Teruya-Feldstein J, Qin J, et al. Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B cell lymphomas. Blood. 2004; 203:1862–1868. [PubMed: 14615382]

Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24:961–968. [PubMed: 16418494]

Kalaitzidis D, Davis RE, Rosenwald A, Staudt LM, Gilmore TD. The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-κB signal transduction pathway. Oncogene. 2002; 21:8759–8768. [PubMed: 12483529]

Kalaitzidis D, Gilmore TD. Genomic organization and expression of the rearranged REL proto-oncogene in the human B-cell lymphoma cell line RC-K8. Genes Chromosomes Cancer. 2002; 34:129–135. [PubMed: 11921291]

Lam LT, Davis RE, Ngo VN, Lenz G, Wright G, Xu W, et al. Compensatory IKKα activation of classical NF-κB signaling during IKKβ inhibition identified by an RNA interference sensitization screen. Proc Natl Acad Sci USA. 2008; 105:20798–20803. [PubMed: 19104039]

Lee HH, Dempsey PW, Parks TP, Zhu X, Baltimore D, Cheng G. Specificities of CD40 signaling: involvement of TRAF2 in CD40-induced NF-κB activation and intracellular adhesion. Proc Natl Acad Sci USA. 1999; 96:1421–1426. [PubMed: 9990039]

Leeman JR, Weniger MA, Barth TF, Gilmore TD. Deletion analysis and alternative splicing define a transactivation inhibitory domain in human oncoprotein REL. Oncogene. 2008; 27:6770–6781. [PubMed: 18695674]

Liang M-C, Bardhan S, Li C, Pace EA, Porco JA Jr, Gilmore TD. Jesterone dimer, a synthetic derivative of the fungal metabolite jesterone, blocks activation of transcription factor nuclear factor κB by inhibiting the inhibitor of κB kinase. Mol Pharmacol. 2003; 64:123–131. [PubMed: 12815168]

Mainou BA, Raab-Traub N. LMP1 strain variants: biological and molecular properties. J Virol. 2006; 80:6458–6468. [PubMed: 16775333]

Martin AG, San-Antonio B, Fresno M. Regulation of nuclear factor κB transactivation: implications of phosphatidylinositol 3-kinase and protein kinase Cζ in c-Rel activation by tumor necrosis factor α. J Biol Chem. 2001; 276:15840–15849. [PubMed: 11278885]
Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature. 2006; 441:106–110. [PubMed: 16572121]

Pavlidis P, Noble WS. Matrix2png: a utility for visualizing matrix data. Bioinformatics. 2003; 19:295–296. [PubMed: 12538257]

Perez JR, Higgins-Sochaski KA, Maltese JY, Narayanan R. Regulation of adhesion and growth of fibrosarcoma cells by NF-κB RelA involves transforming growth factor beta. Mol Cell Biol. 1994; 14:5326–5332. [PubMed: 8035811]

Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM. Mining for regulatory programs in the cancer transcriptome. Nat Genet. 2005; 37:579–583. [PubMed: 15920519]

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med. 2002; 346:1937–1947. [PubMed: 12075054]

Shaffer AL, Rosenwald A, Staudt LM. Decision making in the immune system: Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol. 2002; 2:920–933. [PubMed: 12461565]

Shaffer AL, Tolga Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, et al. IRF4 addiction in multiple myeloma. Nature. 2008; 454:226–231. [PubMed: 18568025]

Shipp MA, Ross KN, Tamayo P, Weng AP, Lutok JL, Aguilar RCT, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002; 8:68–74. [PubMed: 11786909]

Snow AL, Lambert SL, Natkunam Y, Esquival CO, Krams SM, Martinez OM. EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis. J Immunol. 2006; 177:3283–3293. [PubMed: 16920969]

Springer TA, Vonderheide RH. Lymphocyte adhesion through very late antigen 4: evidence for a novel binding site in the alternatively spliced domain of vascular cell adhesion molecule 1 and an additional alpha 4 integrin counter-receptor on stimulated endothelium. J Exp Med. 1992; 175:1433–1442. [PubMed: 1375259]

Starczynowski DT, Reynolds JG, Gilmore TD. Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells. Oncogene. 2003; 22:6928–6936. [PubMed: 14534540]

Starczynowski DT, Reynolds JG, Gilmore TD. Mutations of tumor necrosis factor α-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability. Oncogene. 2005; 24:7355–7368. [PubMed: 16027730]

Starczynowski DT, Trautmann H, Pott C, Harder L, Arnold N, Africa JA, et al. Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL’s in vitro transforming activity. Oncogene. 2007; 26:2685–1694. [PubMed: 17072339]

Stoffel A, Chaurushiya M, Singh B, Levine AJ. Activation of NF-κB and inhibition of p53-mediated apoptosis by AP12/Mucosa-Associated Lymphoid Tissue 1 fusions promote oncogenesis. Proc Natl Acad Sci USA. 2004; 101:9079–9084. [PubMed: 15184680]

van Imhoff GW, Boerma EJ, van der Holt B, Schuuring E, Verdonck LF, Kluin-Nelemans HC, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24:4135–4142. [PubMed: 16943530]

Voorzanger-Rousselot N, Favrot M-C, Blay J-Y. Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood. 1998; 92:3381–3387. [PubMed: 9787177]

Wennborg A, Aman P, Saranath D, Pear W, Sümegi J, Klein G. Conversion of the lymphoma cell line “BJAB” by Epstein-Barr virus into phenotypically altered sublines is accompanied by increased c-myc RNA levels. Int J Cancer. 1987; 40:202–206. [PubMed: 3038758]

Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003; 100:9991–9996. [PubMed: 12900505]
Yamamoto N, Takizawa T, Iwanaga Y, Shimizu N, Yamamoto N. Malignant transformation of B lymphoma cell line BJAB by Epstein-Barr virus-encoded small RNAs. FEBS Lett. 2000; 484:153–158. [PubMed: 11068051]

Zarnegar B, He JQ, Oganesyan G, Hoffman A, Baltimore D, Cheng G. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-κB activation pathways. Proc Natl Acad Sci USA. 2004; 101:8108–8113. [PubMed: 15148378]
Figure 1.
Overexpression of RELΔTAD1 increases the soft agar colony-forming ability of BJAB cells. (a) Structure of MSCV retroviral vectors used in these studies. (b) Anti-REL Western blotting of cells stably transduced with MSCV or MSCV-RELΔTAD1 (RELΔTAD1). Endogenous REL and introduced RELΔTAD1 are indicated. (c) Relative soft agar colony formation of BJAB-MSCV cells (1.0) and BJAB-RELΔTAD1 cells. Values are the averages of four assays performed in triplicate; error bars indicate standard error. (d) Comparison of the proliferation of BJAB-MSCV cells and BJAB-RELΔTAD1 cells. Cells were plated at 10^5 cells/well and were counted each day following plating. (e) BJAB-MSCV cells (MSCV) and BJAB-RELΔTAD1 cells (ΔTAD1) were treated with 1 μg/ml doxorubicin (DOX) for the indicated times and caspase-3 activity was measured or PARP cleavage was monitored by Western blotting (bottom panel). For each cell type, caspase activity is relative to the activity seen with untreated cells at the same time point (1.0). Cell viability was measured after treatment with 1.0 μg/ml of doxorubicin at the indicated time points (right panel). Values are the averages of four (caspase-3 activity) or three experiments (cell viability), each performed with triplicate samples.
Figure 2.
BJAB-RELΔTAD1 cells have increased nuclear REL protein activity as compared to BJAB-MSCV cells. BJAB-RELΔTAD1 cells and BJAB-MSCV cells were compared by subcellular fractionation (a, c), indirect immunofluorescence using an anti-REL primary antiserum (b), and by EMSA analysis of nuclear extracts (d). In (a) and (c), nuclear (N) and cytoplasmic fractions (C) were subjected to Western blotting using equal proportions of each fraction for analysis of REL, p50, RelA, and 14-3-3 and CD40 proteins (as cytoplasmic controls) or RNA polymerase II (as a nuclear control). In (b), the indicated BJAB cells were stained with an anti-REL antibody and viewed by confocal microscopy. The left panel contains BJAB-RELΔTAD1 cells; the middle and right panels show BJAB-MSCV cells. The left and middle panels were imaged using the same exposure time (Exp), while the right panel was imaged using a longer exposure time to detect the low level of endogenous REL in BJAB-MSCV cells. In (d), an EMSA was performed on equalized amounts (5 μg) of nuclear extracts using a κB-site probe from the human MHC1 enhancer. Where indicated, competitions were performed using an excess of cold probe or samples were supershifted (SS) using anti-REL antiserum. The relevant complexes are indicated.
Figure 3.
Analysis of mRNA and protein from select genes in BJAB-MSCV and BJAB-RELΔTAD1 cells. (a) Heat map of NF-κB-specific ABC-target gene expression in BJAB-RELΔTAD1 cells as compared to BJAB-MSCV cells. The map was created using the matrix2png program (Pavlidis and Noble, 2003). The expression scale is shown below the map. (b) RT-PCR of the indicated mRNAs: BCL2, IRF4, CCR7, CD10, VCAM1, REL (as a positive control), and GAPDH (as a normalization control). Water control (-); BJAB-MSCV (MSCV); BJAB-RELΔTAD1 (RELΔTAD1). (c) Western blotting for REL, VCAM1, BCL2, CD40, CD10 and β-actin (as a normalization control) of extracts from BJAB-MSCV cells (MSCV) and BJAB-RELΔTAD1 cells (RELΔTAD1).
Figure 4.
BJAB-RELΔTAD1 cells show increased adherence to culture dishes. (a) BJAB-MSCV and BJAB-RELΔTAD1 cells (1x10^6) were grown in petri dishes for 36 h and imaged at 200 x magnification (top panel); dishes were then washed with PBS and cells in the same field were imaged again ("Washed" panels). The arrows point to a clump of BJAB-RELΔTAD1 cells that adhere to the culture dish. (b) The percentage of attached cells was determined by measuring the total protein content of floating cells isolated directly from the media and from cells that remained attached to the culture dish. The assay was performed with triplicate plates; error bars represent standard error.
Figure 5.
Expression of REL in several human B-lymphoma cell lines. (a) The following human B-lymphoma cell lines were used: BJAB (EBV-negative Burkitt-like lymphoma), SUDHL-4 (DLBCL), RC-K8 (DLBCL), IB4 (umbilical cordblood B-cell lymphoblastoid line infected with EBV), Daudi (EBV-positive Burkitt’s lymphoma), and BL41 (Burkitt’s lymphoma). Lysates were prepared from actively growing cells, and 20 μg of total protein was analyzed by anti-REL Western blotting (top). At the bottom is shown a Coomassie blue-stained gel of equalized total protein extracts. Rel. Amt. indicates the relative amount of REL in each cell type, as compared to BJAB cells (1.0), determined by scanning of the film in the top panel. (b) Anti-REL Western blotting of control BJAB cells, BJAB-RELΔTAD1 cells, control Daudi cells, and a Daudi-RELΔTAD1 cell line. (c) Relative soft agar colony forming ability of control vs Daudi-RELΔTAD1 cells. Assays were performed as in Figure 1c, values are the averages of 5 experiments performed with triplicate plates, and were normalized to the number of colonies obtained with control Daudi cells (1.0).
Table 1
Tumor-forming abilities of BJAB-RELΔTAD1 and BJAB-MSCV cells in SCID mice

| Cell type    | Number of mice injected | Number of tumors | % Tumors formed |
|--------------|-------------------------|------------------|-----------------|
| BJAB-MSCV    | 7                       | 6                | 43%             |
| BJAB-RELΔTAD1| 7                       | 11               | 79%             |

Using a chi-square test, a $P$-value = 0.05 was obtained for the difference in tumor number between control BJAB-MSCV and BJAB-RELΔTAD1 cells.

$^a$Mice were injected above both right and left hind limbs (two injections/mouse) with $5 \times 10^6$ cells/site.

$^b$Tumors were monitored for up to 7 weeks post-injection.

$^c$Percentage of tumor formation (tumors/14 injection sites $\times 100$).
### Table 2

mRNAs upregulated at least ten-fold in BJAB-RELΔTAD1 cells

| Gene          | Gene function                  | Fold upregulated | P-value | ABC-gene | NF-kB target |
|---------------|--------------------------------|------------------|---------|----------|--------------|
| NFAM1         | B-cell receptor signaling      | 121.2            | 0.00001 |          |              |
| NCAM2         | Neural adhesion                | 80.7             | ≤1E-46  |          |              |
| CXCR7         | Chemokine receptor signaling   | 77.5             | 2.28E-29|          |              |
| FSTL5         | Calcium ion binding            | 72.6             | ≤1E-46  |          |              |
| THC2683057    | Apoptosis                      | 61.9             | 3.42E-07|          |              |
| CB123670      | -                              | 59.7             | ≤1E-46  |          |              |
| MARCKS        | Actin cytoskeleton             | 49.4             | 2.18E-35| +        |              |
| C10orf110     | Progesterone signaling         | 39.4             | ≤1E-46  |          |              |
| BC128163      | Protease inhibitor             | 37.7             | 2.61E-28|          |              |
| SEMA3A        | Neuron development             | 37.3             | ≤1E-46  |          |              |
| MLPH          | Acute binding                  | 35.9             | 7.87E-42|          |              |
| SOCS2         | Regulates cell growth          | 35.1             | 3.10E-08|          |              |
| AFAP          | Inflammation                   | 33.5             | ≤1E-46  |          |              |
| ZC3H12C       | Zinc ion binding               | 32.8             | 8.26E-23|          |              |
| IRF4          | T-cell activation              | 32.2             | ≤1E-46  | +        | +            |
| CX3CL1        | Chemokine ligand               | 32.1             | 7.48E-39|          |              |
| PCOLCE2       | Heparin binding                | 30.3             | ≤1E-46  |          |              |
| INPP4B        | Signaling phosphatase          | 28.7             | ≤1E-46  |          |              |
| CD44          | Cell adhesion                  | 26.3             | 8.24E-40| +        | +            |
| CIC12         | Chloride ion binding           | 25.6             | 2.25E-41|          |              |
| PLD1          | Signal transduction            | 25.5             | ≤1E-46  |          |              |
| ESR1          | Estrogen signaling             | 25.1             | 6.11E-25|          |              |
| REL           | Transcription factor           | 25.1             | ≤1E-46  |          |              |
| VCAM1         | Cell adhesion                  | 24.4             | 2.98E-38|          |              |
| PTGER4        | Prostaglandin signaling        | 22.2             | ≤1E-46  |          |              |
| CUTL2         | Transcription                  | 21.5             | 1.54E-38|          |              |
| Gene          | Gene function               | Fold upregulated | P-value | ABC-gene | NF-κB target |
|---------------|----------------------------|------------------|---------|----------|--------------|
| FLJ42709      |                            | 21.5             | ≤1E-46  |          |              |
| THC2656563    |                            | 21.1             | ≤1E-46  |          |              |
| CCL22         | Inflammation signaling     | 20.7             | ≤1E-46  | +        | +            |
| SERPINB10     | Endopeptidase inhibitor    | 20.6             | 8.05E-30|          |              |
| DMD           | Actin binding              | 19.3             | 3.24E-18|          |              |
| FLJ20605      | Oxidation/reduction        | 19.1             | ≤1E-46  |          |              |
| GFRA1         | Receptor signaling         | 18.8             | 4.64E-34|          |              |
| PTPRN2        | Phosphatase                | 17.0             | 9.63E-31|          |              |
| MSR1          | Receptor-mediated endocytosis| 16.4             | ≤1E-46  |          |              |
| CAMK4         | Calcium ion binding        | 16.2             | 1.42E-15|          |              |
| C1orf133      |                            | 15.6             | 1.84E-08|          |              |
| SPATA16       | Spermatogenesis            | 15.4             | 2.98-13 |          |              |
| LOC653117     |                            | 15.3             | ≤1E-46  |          |              |
| AK027257      |                            | 14.8             | 1.07E-08|          |              |
| PTPN3         | Signaling phosphatase      | 14.3             | ≤1E-46  |          |              |
| STS1A6        | Protein trafficking        | 14.2             | 1.95E-20|          |              |
| BCL2          | Anti-apoptosis             | 13.6             | ≤1E-46  | +        | +            |
| SERTAD4       |                            | 13.6             | ≤1E-46  |          |              |
| KCNMB1        | Calcium-activated potassium channel activity | 13.5 | ≤1E-46 |          |              |
| MNDA          | Transcription              | 13.4             | 1.95E-16|          |              |
| THC2649506    |                            | 13.3             | 9.17E-19|          |              |
| AF086044      |                            | 13.0             | 5.15E-17|          |              |
| KIF26B        | Microtubule binding        | 12.7             | 5.35E-11|          |              |
| ADAMDEC1      | Integrin binding           | 12.6             | ≤1E-46  |          |              |
| SDPR          | Protein binding            | 12.6             | 2.64E-32|          |              |
| LOC51760      | Transporter activity       | 12.5             | 3.69E-41|          |              |
| FBLN1         | Extracellular matrix structural constituent | 12.5 | ≤1E-46 |          |              |
| Gene             | Gene function               | Fold upregulated | P-value     | ABC-gene $^a$ | NF-κB target $^b$ |
|------------------|-----------------------------|------------------|-------------|--------------|------------------|
| X86816           | Estrogen signaling          | 12.2             | 6.03E-19    |              |                  |
| BDKRB1           | Bradykinin receptor activity| 11.8             | 1.27E-24    | +            |                  |
| CCL17            | Chemokine activity          | 11.8             | 2.32E-33    | +            |                  |
| SGPP2            | Hydrolase activity          | 11.8             | 2.37E-27    |              |                  |
| TPCN2            | Calcium channel activity    | 11.1             | 1.29E-22    |              |                  |
| A_23_P106814     | -                           | 11.0             | 6.65E-24    |              |                  |
| ZBTB32           | Transcription               | 10.9             | ≤1E-46      |              |                  |
| FLJ42342         | -                           | 10.9             | 3.07E-35    |              |                  |
| LOC124220        | Sugar binding               | 10.6             | ≤1E-46      |              |                  |
| D4S234E          | Dopamine receptor binding   | 10.5             | 2.51E-08    |              |                  |
| LOC646627        | Phospholipase inhibitor     | 10.4             | 1.25E-21    |              |                  |
| EPB4114B         | Cytoskeleton protein binding| 10.3             | 2.79E-10    |              |                  |
| ENST00000321715  | -                           | 10.2             | 2.06E-32    |              |                  |
| TP73L            | DNA binding                 | 10.1             | 6.1E-44     |              |                  |

$^a$ABC-gene refers to a gene classified as being overexpressed in ABC-DLBCL (Alizadeh et al., 2000; Shipp et al., 2002; Wright et al., 2003; Feuerkhake et al., 2005; Ngo et al., 2006).

$^b$NF-κB targets are classified based on [www.nf-kb.org](http://www.nf-kb.org).
Table 3
ABC and GCB genes whose expression is altered in RELΔTAD-BJAB cells

| Gene type                  | Total number of genes | No. upregulated | No. downregulated | No. unchanged |
|----------------------------|-----------------------|-----------------|-------------------|--------------|
| All ABC-specific genes     | 102                   | 31 (30%)        | 12 (12%)          | 59 (58%)     |
| ABC-NF-κB targets          | 29                    | 17 (59%)        | 2 (7%)            | 10 (34%)     |
| All GCB-specific genes     | 62                    | 6 (10%)         | 15 (24%)          | 41 (66%)     |
| GCB-NF-κB targets          | 3                     | 2 (67%)         | 1 (33%)           | 0 (0%)       |

Gene lists were obtained using previously classified ABC and GCB-specific genes (Alizadeh et al., 2000; Rosenwald et al., 2002; Wright et al., 2002; Feuerkhake et al., 2005; Ngo et al., 2006) and NF-κB targets were obtained from www.nf-kb.org. See Tables S2 and S3 for complete gene lists, references and annotations. Listed are the numbers of genes that are upregulated, downregulated or unchanged in RELΔTAD1 cells compared to BJAB-MSCV cells within a given subset. The genes with altered expression were classified based on a P-value cut-off of 0.005. Genes were grouped into ABC-specific genes, ABC-specific NF-κB targets, GCB-specific genes and GCB-specific NF-κB target genes. To validate the patterns of ABC and GCB gene expression distribution in BJAB-RELΔTAD1 cells, we calculated the P-value of the two gene sets (ABC, 31 and 12 versus GCB, 6 and 15) using a two-tailed chi-square test at 95% confidence using Graphpad Prism 4 software (Graphpad Prism Software, San Diego, CA). These two gene sets differed with a highly significant P-value (0.0009). That is, the percentage of upregulated ABC-genes and the percentage of downregulated GCB-genes in BJAB-RELΔTAD1 cells are significantly different from one another.
## Table 4
Gene Ontology classifications for upregulated genes in the BJAB-RELΔTAD1 cells

| Gene ontology                                | No. of genes | P-value          |
|----------------------------------------------|--------------|------------------|
| **Protein function**                         |              |                  |
| Intrinsic to plasma membrane                 | 73           | 2.80 × 10^{-10}  |
| Extracellular region part                    | 52           | 9.70 × 10^{-9}   |
| Cell communication                           | 157          | 3.10 × 10^{-8}   |
| Signal transduction                          | 144          | 1.30 × 10^{-7}   |
| Biological adhesion                          | 45           | 7.60 × 10^{-7}   |
| Immune response                              | 50           | 2.00 × 10^{-6}   |
| Membrane part                                | 205          | 5.50 × 10^{-6}   |
| Protein binding                              | 227          | 3.60 × 10^{-6}   |
| **Biological function**                      |              |                  |
| Diseases and disorders                       |              |                  |
| Immunological disease                        | 75           | 1.12 × 10^{-10}–1.99 × 10^{-3} |
| Connective tissue disorder                   | 52           | 5.07 × 10^{-9}–1.50 × 10^{-3} |
| Molecular and cellular functions             |              |                  |
| Cellular growth and proliferation            | 144          | 4.88 × 10^{-10}–1.88 × 10^{-3} |
| Cell to cell signaling and interaction       | 114          | 1.73 × 10^{-9}–1.50 × 10^{-3} |
| Physiological system development and function|              |                  |
| Immune and lymphatic system development and function | 84  | 2.01 × 10^{-10}–1.98 × 10^{-3} |
| Tissue morphology                            | 71           | 2.01 × 10^{-10}–1.88 × 10^{-3} |

Gene Ontology grouping of the functions of the upregulated genes (563 annotated total) in RELDTAD1 cells. Shown at the top are the protein functions of the GO-terminology groupings with the lowest P-values (http://david.abcc.ncifcrf.gov/). In the bottom half of the table are the biological groupings of 421 significantly upregulated genes that were annotated in the Ingenuity Pathways Analysis program (www.ingenuity.com). Shown are the classifications based on the lowest P-values. Ranges of P-values refer to the fact that multiple subcategories are included in these classifications.